Free Trial

Theravance Biopharma (TBPH) 10K Form and Latest SEC Filings 2026

Theravance Biopharma logo
$16.73 -0.18 (-1.06%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$16.73 0.00 (0.00%)
As of 05/5/2026 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Theravance Biopharma SEC Filings & Recent Activity

Theravance Biopharma (NASDAQ:TBPH) has submitted 599+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Theravance Biopharma's financial statements. The most recent filing was a Form DEF 14A submitted on April 28, 2026.

Form 4
Theravance Biopharma, Inc. Reports Ownership Change on Apr. 3, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Theravance Biopharma Files Current Report on Mar. 30, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Theravance Biopharma Files Annual Report on Mar. 23, 2026

The 10-K contains Theravance Biopharma's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Theravance Biopharma SEC Filing History

Browse Theravance Biopharma's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/28/2026 3:59 PM
Theravance Biopharma (1583107) Filer
Form DEF 14A
04/03/2026 5:03 PM
Farnum Rhonda (1898490) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/03/2026 5:06 PM
Grimaud Brett A. (1966698) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/03/2026 5:08 PM
Sawaf Aziz (1961289) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/03/2026 5:10 PM
Theravance Biopharma (1583107) Issuer
Winningham Rick E (1302443) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/30/2026 4:34 PM
Theravance Biopharma (1583107) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/25/2026 3:05 PM
Theravance Biopharma (1583107) Subject
Weiss Asset Management LP (1357550) Filed by
Form SCHEDULE 13D/A
03/23/2026 7:46 AM
Theravance Biopharma (1583107) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/19/2026 7:38 AM
Theravance Biopharma (1583107) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/18/2026 5:12 PM
Farnum Rhonda (1898490) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 7:35 AM
Theravance Biopharma (1583107) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/24/2026 6:35 PM
Farnum Rhonda (1898490) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 6:37 PM
Grimaud Brett A. (1966698) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 6:38 PM
Miller Aine (2012524) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 6:40 PM
Sawaf Aziz (1961289) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 6:43 PM
Theravance Biopharma (1583107) Issuer
Winningham Rick E (1302443) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 7:01 AM
Theravance Biopharma (1583107) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/08/2025 5:29 AM
Theravance Biopharma (1583107) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/05/2025 5:02 PM
Farnum Rhonda (1898490) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/03/2025 3:19 PM
Farnum Rhonda (1898490) Reporting
Theravance Biopharma (1583107) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/01/2025 6:02 PM
BROSHY ERAN (1256230) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/24/2025 5:11 PM
Farnum Rhonda (1898490) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/24/2025 5:13 PM
Grimaud Brett A. (1966698) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/24/2025 5:15 PM
Miller Aine (2012524) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/24/2025 5:16 PM
Sawaf Aziz (1961289) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/21/2025 6:10 PM
Theravance Biopharma (1583107) Issuer
Winningham Rick E (1302443) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 5:00 AM
BROSHY ERAN (1256230) Reporting
Theravance Biopharma (1583107) Issuer
Form 4/A
11/13/2025 8:00 PM
BROSHY ERAN (1256230) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2025 8:02 AM
BROSHY ERAN (1256230) Reporting
Theravance Biopharma (1583107) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/25/2025 5:04 AM
Theravance Biopharma (1583107) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/22/2025 5:09 PM
Theravance Biopharma (1583107) Issuer
Winningham Rick E (1302443) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2025 5:01 PM
Farnum Rhonda (1898490) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2025 5:03 PM
Grimaud Brett A. (1966698) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2025 5:05 PM
Miller Aine (2012524) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2025 5:07 PM
Sawaf Aziz (1961289) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2025 5:05 AM
Theravance Biopharma (1583107) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/13/2025 4:11 PM
Theravance Biopharma (1583107) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/16/2025 5:01 PM
Farnum Rhonda (1898490) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/14/2025 3:03 PM
Farnum Rhonda (1898490) Reporting
Theravance Biopharma (1583107) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/26/2025 5:05 AM
Theravance Biopharma (1583107) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/25/2025 5:06 PM
Theravance Biopharma (1583107) Issuer
Winningham Rick E (1302443) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025 5:16 PM
Theravance Biopharma (1583107) Issuer
Winningham Rick E (1302443) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025 5:03 AM
Theravance Biopharma (1583107) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/04/2025 5:04 PM
Farnum Rhonda (1898490) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/02/2025 3:25 PM
Farnum Rhonda (1898490) Reporting
Theravance Biopharma (1583107) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/02/2025 5:02 AM
Theravance Biopharma (1583107) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/22/2025 5:39 PM
Farnum Rhonda (1898490) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2025 5:41 PM
Grimaud Brett A. (1966698) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2025 5:42 PM
Sawaf Aziz (1961289) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2025 5:44 PM
Theravance Biopharma (1583107) Issuer
Winningham Rick E (1302443) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 6:00 PM
Smaldone Alsup Laurie (1589602) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 6:02 PM
BROSHY ERAN (1256230) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 6:10 PM
Grant Jeremy T (2004368) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 6:13 PM
GRAY SUSANNAH (1833453) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 6:15 PM
MITCHELL DEAN J (1199297) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 6:17 PM
O'Connor Donal (1625377) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 6:20 PM
PAKIANATHAN DEEPIKA (1270734) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 6:22 PM
Miller Aine (2012524) Reporting
Theravance Biopharma (1583107) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2025 3:29 PM
Theravance Biopharma (1583107) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Theravance Biopharma SEC Filings - Frequently Asked Questions

Theravance Biopharma (TBPH) has submitted 599+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Theravance Biopharma's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Theravance Biopharma's financial statements page.

The most recent filing was a Form DEF 14A submitted on April 28, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:TBPH) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners